TY - JOUR
T1 - Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients
AU - Gualano, Bruno
AU - Lemes, Ítalo Ribeiro
AU - da Silva, Rafael Pires
AU - Pinto, Ana Jéssica
AU - Mazzolani, Bruna Caruso
AU - Smaira, Fabiana Infante
AU - Sieczkowska, Sofia Mendes
AU - Aikawa, Nádia Emi
AU - Pasoto, Sandra
AU - Medeiros-Ribeiro, Ana Cristina
AU - Saad, Carla
AU - Yuk, Emily
AU - Silva, Clovis
AU - Swinton, Paul
AU - Hallal, Pedro Curi
AU - Roschel, Hamilton
AU - Bonfa, Eloisa
N1 - Funding Information:
The authors are thankful to Marta H. Lopes, Tatiana Pedrosa, Antonio José Rodrigues Pereira, Solange Fusco, Priscila Tagliaferro Rojo, and Central Laboratory Division of the Clinical Hospital of the School of Medicine (University of São Paulo) for the technical assistance.
Funding Information:
This trial is sponsored by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (#2015/03756–4 to NEA, SGP, CAS and EB; #2015/26937–4 to AJP; #2017/13552–2 to BG; #2020/04877–8 to IRL; #2017/23688–9 to RPS; #2019/14820–6 to BCM; #2019/14819–8 to FIS; #2019/15231–4 to SMS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (#305242/2019–9 to EB, #304984/2020–5 to CAS), B3 – Bolsa de Valores do Brasil, and Instituto Todos pela Saúde (ITPS 01/2021, C1313 to E.B., C.A.S., N.E.A. and S.G.P.). Instituto Butantan supplied the study's product and had no other role in the trial.
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2022/10
Y1 - 2022/10
N2 - This prospective cohort study within an open-label, single-arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti-SARS-CoV-2 antibodies 6 months after two-dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full-course vaccination was assessed using seroconversion rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full-course of an inactivated SARS-CoV-2 vaccine.
AB - This prospective cohort study within an open-label, single-arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti-SARS-CoV-2 antibodies 6 months after two-dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full-course vaccination was assessed using seroconversion rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full-course of an inactivated SARS-CoV-2 vaccine.
KW - autoimmune rheumatic disease
KW - COVID-19
KW - immunosuppression
KW - physical activity
KW - vaccine responses
UR - http://www.scopus.com/inward/record.url?scp=85134766039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134766039&partnerID=8YFLogxK
U2 - 10.1111/sms.14213
DO - 10.1111/sms.14213
M3 - Article
C2 - 35844042
AN - SCOPUS:85134766039
SN - 0905-7188
VL - 32
SP - 1510
EP - 1515
JO - Scandinavian Journal of Medicine and Science in Sports
JF - Scandinavian Journal of Medicine and Science in Sports
IS - 10
ER -